Japan· JP-4490028F4069
レボセチリジン塩酸塩
A levocetirizine product containing レボセチリジン塩酸塩, registered in Japan by 日新製薬（山形）, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Levocetirizine is registered in 16 of 19 countries.
Countries holding a registration under ATC R06AE09 (levocetirizine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 10 of them publish a price we can compare per daily dose
Levocetirizine · ATC R06AE09
16 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of levocetirizine costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.15 in France to $0.53 in Switzerland — a ×3.4 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Levocetirizine · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.53
- ES Spain$0.34
- IT Italy$0.21
- FR France$0.15
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レボセチリジン塩酸塩
- Manufacturer
- 日新製薬（山形）
- Country
- Japan (JP)
- ATC code
- R06AE09
- ATC class
- Levocetirizine
- Defined daily dose
- 5 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
267 interactions on record for levocetirizine.
Graded by severity as the source publishes them — 264 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levocetirizine · interactions on record
267 records
- 264 moderate
- 3 minor
Most severe, free to view
- MetoclopramideA03FA01moderate
- DimenhydrinatA04AB02moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R06AE09
Levocetirizine, as other registers publish it.
- United States24HR Allergy ReliefLEADER/ Cardinal Health 110, Inc.
- PolandAlcetyrArtespharm Sp. z o.o.
- PolandAlergimedDr. Max Pharma s.r.o.
- CzechiaALERGIMEDMEDREG s.r.o., Praha
- CzechiaALERGIMEDMEDREG s.r.o., Praha
- CzechiaALERGIMEDMEDREG s.r.o., Praha
- CzechiaALERGIMEDMEDREG s.r.o., Praha
- CzechiaALERGIMEDMEDREG s.r.o., Praha
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb8a6188-5ac1-4d69-a2f2-3a81bc5fe1f7 GET /v1/drugs/bb8a6188-5ac1-4d69-a2f2-3a81bc5fe1f7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4490028F4069",
"category": "内用薬",
"price_yen": 13.4,
"generic_name": "レボセチリジン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "4490",
"transitional_expiry": null
}See everything about levocetirizine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.